Fig. 3
LPA1 antagonism reduces brain damage at 3 days after tMCAO challenge. Mice were challenged with tMCAO. AM095 (30 mg/kg, p.o.) was then administered immediately after reperfusion. Brain damage was assessed at 3 days after tMCAO. a–c Effects of AM095 on infarct volume (a, b) and neurological function (c) were determined. Representative images of TTC-stained brain slices (a) and quantification of brain infarction (b). Neurological score indicating neurological functions (c). n = 8 mice per group. **p < 0.01 and ***p < 0.001 versus vehicle-administered tMCAO mice (tMCAO+veh)